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Abstract. Background: We retrospectively compared adenosine
triphosphate-based chemotherapy response assay (ATP-CRA)-
guided and empirical chemotherapies for unresectable non-
small cell lung cancer (NSCLC) in this case-control study.
Patients and Methods: Unresectable NSCLC patients receiving
ATP-CRA-guided platinum-based doublets as first-line therapy
were enrolled as cases (n=27; 14 platinum-sensitive and 13
platinum-resistant patients). Performance status, stage, and
chemotherapeutic regimen-matched patients receiving empirical
chemotherapy were selected from the retrospective database as
controls (n=93) in a case to control ratio of ~1:3. Results:
Response rate and survival (progression-free; overall) in both
groups were not significantly different. However, the platinum-
sensitive subgroup by ATP-CRA showed a higher response rate
than the empirical group (71 versus 38% ; p=0.023) with a
trend toward longer progression-free survival (8.7 versus 4.8
months for platinum-sensitive versus empirical; p=0.223) and
overall survival (not reached versus 12.6 months for platinum-
sensitive versus empirical for p=0.134). Conclusion: ATP-CRA
may be helpful in selecting platinum-responsive patients in
unresectable NSCLC. We consider that nonplatinum doublets in
platinum-resistant patients by ATP-CRA may be a more adapted
approach than platinum-based doublets in future clinical trials. 
Non-small cell lung cancer (NSCLC) is the leading cause of
cancer-related death around the world (1). Most patients
with NSCLC eventually succumb to distant metastasis.
Despite advances in palliative chemotherapy, however, the
prognosis of advanced NSCLC is still very poor. To
overcome this limitation, attention is turning to developing
of techniques that could provide predictive information
regarding a particular tumors chemosensitivity, as a means
of enhancing patient selection for a specific chemotherapy
option. This is based on the concept developed 30 years ago
of selecting chemotherapeutic agents for an individual
patient by in vitro drug sensitivity testing (2).
With this background, we have already reported the
outcomes of an in vitro chemosensitivity test, adenosine
triphosphate-based chemotherapy response assay (ATP-CRA)-
guided platinum-based two-drug chemotherapy for
unresectable NSCLC (3). The methodology of ATP-CRA was
feasible as an in vitro chemosensitivity and resistance assay
before chemotherapy. This assay had the advantages of a short
test turnaround time of 7 days and a high assay success rate of
89% , despite using a limited volume of tumor sample from
bronchoscopic biopsies (3, 4). The study showed more
favorable responses and survival in the chemosensitive
subgroup than in the chemoresistant subgroup within the assay-
guided chemotherapy group. However, our previous study was
not randomized in order to compare in vitro assay-guided
chemotherapy to empirical chemotherapy. As a result, the
clinical benefit of in vitro assay-guided chemotherapy remained
unanswered. This motivated us to perform the current study
that compares ATP-CRA-guided chemotherapy to empirical
chemotherapy in unresectable NSCLC. In the current study,
prospective data of patients extracted from the previous
reported trial with ATP-CRA-guided chemotherapy (3) were
compared to retrospective data of patients receiving empirical
chemotherapy in unresectable NSCLC. 
4243
*Presented in part at the 12th World Lung Cancer Conference,
Seoul, Korea. Sept 2-6, 2007.
Correspondence to: Joo-Hang Kim, MD, Ph.D., Yonsei Cancer
Center, Department of Internal Medicine, Yonsei University College
of Medicine, 134 Shinchon-Dong, Seodaemun-gu, CPO Box 8044,
Seoul 120-752, Korea. Tel: +82 222288132, Fax: +82 23933652,
e-mail: kjhang@yuhs.ac
Key Words: Non-small cell lung cancer, in vitro assay-guided
chemotherapy, empirical chemotherapy. 
ANTICANCER RESEARCH 29: 4243-4250 (2009)
Adenosine Triphosphate-based Chemotherapy Response 
Assay (ATP-CRA)-guided versus Empirical Chemotherapy
in Unresectable Non-small Cell Lung Cancer*
YONG WHA MOON1,2, JOO HYUK SOHN1,2, YONG TAI KIM3, HYUN CHANG1,2, 
JAE HEON JEONG1,2, YOUNG JOO LEE1,2, JOON CHANG2, SE KYU KIM2, 
MINKYU JUNG1,2, SOOJUNG HONG1,2, SUNG HO CHOI4 and JOO-HANG KIM1,2 
1Yonsei Cancer Center and 2Department of Internal Medicine, Yonsei University College of Medicine, Seoul; 
3Division of Hemato-Oncology, National Health Insurance Corporation Ilsan Hospital, Gyeonggi-do;
4ISU ABXIS CO., LTD., Seoul, Korea
0250-7005/2009 $2.00+.40
Patients and Methods
Patients. Between January 2004 and December 2005, we
prospectively performed ATP-CRA-guided platinum-based doublet
chemotherapy for chemonaïve, unresectable NSCLC under a clinical
trial setting (3). Medical records of unresectable NSCLC patients
diagnosed at the same period and receiving platinum-based empirical
chemotherapy were retrospectively reviewed. Through retrospective
review, patients who met the following criteria were eligible: i)
histologically or cytologically proven NSCLC, ii) stage IIIB or IV
disease [American Joint Cancer Committee (AJCC) staging 2002]
(5), iii) receiving at least one cycle of platinum-based doublet
chemotherapy, iv) Eastern Cooperative Oncology Group performance
status (ECOG PS) ≤2, v) adequate organ function, vi) no previous
chemo- or radiotherapy, and vii) no history of other malignancies
(excluding nonmelanoma skin cancer or carcinoma in-situ of the
uterine cervix) within 5 years. From 341 eligible patients by
retrospective review, ECOG PS (0-1 versus 2)-, stage (IIIB versus
IV)-, and chemotherapy regimen (platinum plus gemcitabine versus
paclitaxel versus vinorelbine)-matched patients were randomly
selected at a case to control ratio of ~1:3 between the assay-guided
(cases) and empirical chemotherapy (controls) groups (Figure 1). 
Chemotherapy response and survival were compared between the
assay-guided and empirical chemotherapy groups. This study was
approved by the Institutional Review Board of Severance Hospital,
Yonsei University Health System.
ATP-CRA methodology. ATP-CRA was performed as described
elsewhere (3, 4). Briefly, cancer cells were isolated from tumor tissues
and normal cells were specifically eliminated. Separated tumor cells
were diluted using Iscove's Modified Dulbecco's Medium (IMDM)
(GIBCO BRL, Rockville, MD, USA), including 10%  fetal bovine
serum (GIBCO BRL, Rockville, MD, USA), and seeded on an ultra-
low attachment plate (Costar, Cambridge, MA, USA). In the treated
groups, chemotherapeutic agents were added to the seeded cell
cultures which were then incubated. In the untreated control groups,
IMDM without chemotherapeutic agents was added. Cells from the
untreated control and treated groups were lysed and the amount of ATP
in the cell lysates was measured as previously described. The cell
death rate for each drug was defined as the rate of ATP luminescence
reduction in the treated group compared to the untreated control.
Chemotherapy. In the assay-guided treatment group, a drug sensitivity
was defined as a drug producing a 30%  or more reduction in ATP
compared to untreated controls (3, 6). All the patients received platinum-
based two-drug chemotherapy regardless of their in vitro platinum-
sensitivity. One of the following nonplatinum drugs combined with
platinum was chosen based on the ATP-CRA results as recently reported
(3): gemcitabine (1,000 mg/m2, days 1 and 8, every 3 weeks), paclitaxel
(175 mg/m2, day 1, every 3 weeks), or vinorelbine (30 mg/m2, days 1
and 8, every 3 weeks). In cases sensitive to no drug in vitro, the drug
with the highest cell death rate was chosen. In the empirical group, a
nonplatinum agent was chosen depending on physicians’ discretion and
administered in the same dosing schedules as the assay group. Platinum
choice [cisplatin (75 mg/m2, every 3 weeks) or carboplatin (area under
the curve of 5, every 3 weeks)] was determined by renal function and
ECOG PS similarly in both groups; carboplatin was preferred in cases of
creatinine clearance ≤60 ml/min or PS of 2. Chemotherapy was
delivered up to a maximum of 6 cycles or until the appearance of
progressive disease.
Analysis of end points and statistical considerations. The primary
end point was the clinical response rate (RR). Response was
assessed every 2 cycles. Tumor response was evaluated according
to the Response Evaluation Criteria in Solid Tumors (7). The
secondary end points were progression-free survival (PFS) and
overall survival (OS). PFS was defined as the time from
commencement of chemotherapy until progression or death. OS was
defined as the time from chemotherapy to death from all causes. 
All statistical calculations were carried out using SPSS for
Windows, version 12.0 (SPSS Inc., USA). All p-values were two-
sided and the α-value was set at 0.05. Chi-square or Fisher exact test
was used to compare categorical variables. Survival was calculated
using the Kaplan-Meier method. A log-rank test was used to compare
survival between groups. Multivariate analysis for prognosticators was
performed by Cox’s proportional hazard regression model.
Results
Patients characteristics. In the assay group, 27 patients were
included (Table I). Ninety-three corresponding patients with
matched prognosticators were included in the empirical group
(Table I). All matched ratios were ~1:3, meeting
appropriately targeted ratio except ECOG PS of 2 (1:2.5 for
assay:empirical). In spite of this, matched prognosticators,
namely, ECOG PS, stage and chemotherapeutic regimen were
well-balanced statistically between the two groups. ECOG PS
was 0-1 in 87.1-89.2%  and 2 in 10.8-12.9% . The stages of
patients were IIIB in 30.1-33.3%  and IV in 66.7-69.9% . The
nonplatinum agents administered were paclitaxel in 40.7-
42.0% , gemcitabine in 33.3% , and vinorelbine in 24.7-
26.0% . Variables other than matched prognosticators were
not different between the two groups, either. However, in the
assay group, carboplatin was used slightly more frequently
(29.6 versus 17.2% ; p=0.155) and brain metastasis was a
little more common (18.5 versus 10.8% ; p=0.283). 
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Figure 1. Method of patient selection. PS, Performance status; pts,
patients. The assay group (n=27) and whole population of empirical
chemotherapy (n=341) were divided into subgroups 1 to 12 according to
PS, stage and chemotherapy regimen. From subgroups 1 to 12 of the
whole population of empirical chemotherapy, patients were randomly
selected at a ratio of 1:3 to 1:4 between the assay (cases) and empirical
chemotherapy groups (controls). 
Within the assay group, ATP-CRA results were as follows:
8 patients were sensitive to both platinum and nonplatinum
agents, 6 patients were sensitive to platinum alone, 6 patients
were sensitive to nonplatinum agents alone, and 7 patients
were sensitive to neither drug. When the former 2 subgroups
were categorized as the ‘platinum-sensitive group’ (n=14)
and the latter 2 subgroups as the ‘platinum-resistant group’
(n=13), there were no significant differences in pretreatment
parameters such as ECOG PS, histology and stage between
these two groups (data not shown). 
Comparison of response between assay-guided versus
empirical groups. Median number of cycles administered were
3 (range, 1-6) and 4 (range, 1-9), with median relative dose
intensities of 85.7%  and 81.8%  for the assay-guided and
empirical groups, respectively. Chemoradiotherapy was
administered to 2 patients (7.4% ) in the assay-guided group
and 11 (11.8% ) in the empirical group. Two patients (7.4% )
received curative-intent surgery in the assay-guided group after
chemotherapy and 3 patients (3.2% ) in the empirical group.
Only 1 patient from the empirical group was not assessable
for response due to loss of follow-up after the 1st cycle of
chemotherapy. Within the assay group, the RR was significantly
higher in the platinum-sensitive group (71.4% ) than that in the
platinum-resistant group (23.1% ; p=0.021). However, when the
platinum-sensitive and -resistant groups were combined in the
assay group, the assay group only had a trend toward a slightly
higher RR than the empirical group (48.1 versus 38.0%  for the
assay versus empirical group; p=0.347; Table II) under the
intent-to-treat analysis. In spite of this, the platinum-sensitive
group still showed a higher response rate than the empirical
group (Figure 2; p=0.023). In the subgroup analysis according
to nonplatinum agents, the paclitaxel group had a trend toward
a higher response rate that favored assay-guided chemotherapy
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Table I. Patient characteristics.
Assay group (n=27) Matched ratio Empirical group (n=93)
N (% ) Ass:Emp N (% ) P-valuea
Median age (years) (range) 62 (33-76) - 59 (29-74) 0.529
Gender
Male 16 (59.3) - 59 (63.4) 0.693
Female 11 (40.7) - 34 (36.6)
ECOG performance status
0-1 23 (89.2) 1:3.6 83 (87.1) 0.797
2 4 (10.8) 1:2.5 10 (12.9)
Histology
Adenocarcinoma 16 (59.3) - 46 (49.5) 0.456
Squamous cell carcinoma 10 (37.0) - 36 (38.7)
Other 1 (3.7) - 11 (11.8)
Stage
IIIB 9 (33.3) 1:3.1 28 (30.1) 0.749
IV 18 (66.7) 1:3.6 65 (69.9)
Brain metastasis
Absent 22 (81.5) - 83 (89.2) 0.283
Present 5 (18.5) - 10 (10.8)
Chemotherapy regimen
Gemcitabine+platinum 9 (33.3) 1:3.4 31 (33.3) 0.990
Paclitaxel+platinum 11 (40.7) 1:3.5 39 (42.0)
Vinorelbine+platinum 7 (26.0) 1:3.3 23 (24.7)
Platinum
Cisplatin 19 (70.4) - 77 (82.8) 0.155
Carboplatin 8 (29.6) - 16 (17.2)
Assay results within assay group
Platinum-sensitive 14 (51.9) - - -
Sensitive to both drugs 8
Sensitive to platinum alone 6
Platinum-resistant 13 (48.1) - - -
Sensitive to nonplatinum drug 6
Sensitive to neither drug 7
Ass: Assay group, Emp: empirical group. ap-value was calculated by Chi-square test or Fisher’s exact test except for age (Mann-Whitney test).
(p=0.147; Table II). In the gemcitabine and vinorelbine group,
there were no differences in response between assay-guided and
empirical chemotherapy (Table II). 
Comparison of progression-free and overall survival between
assay-guided versus empirical groups. Eight patients were
excluded from the PFS analysis: 1 (an early drop-out
because of the patient’s refusal) from the assay group and 7
(an unclear date of progression) from the empirical group.
At the median follow-up duration of 11.2 months, 23
(88.5% ) out of the 26 patients in the assay group and 80
(93.0% ) out of the 86 patients in the empirical group
experienced disease progression. Within the assay group, the
platinum-sensitive subgroup showed a significantly longer
PFS than the platinum-resistant subgroup (p=0.047). There
was also a trend toward the longest PFS in the platinum-
sensitive group [median, 8.7 months, 95%  confidence
interval (CI) 2.6-14.8 months], followed by the empirical
group (median, 4.8 months, 95%  CI 3.5-6.1 months) and
then the platinum-resistant group (median, 2.4 months, 95%
CI 1.9-2.9 months) although these differences were not
statistically significant (Figure 3A). However, no difference
in median PFS was observed between the assay and
empirical groups (4.4 versus 4.8 months for assay versus
empirical; p=0.918; Figure 3C; Table II).
Sixteen (69.6% ) out of 23 progressive patients from the
assay group and 60 (75.0% ) out of 80 progressed patients
from the empirical group received 2nd-line chemotherapy.
All the patients were included in the OS analysis. Fifteen
(55.6% ) out of the 27 patients in the assay group and 56
(60.2% ) out of the 93 patients in the empirical group died.
All deaths were caused by cancer progression except 2 (1
pneumonia in the assay group, 1 traffic accident in the
empirical group). Although within the assay group median
OS was longer in the platinum-sensitive subgroup (not
reached) than that in the platinum-resistant subgroup (11.0
months; p=0.068), there was no difference in median OS
between the assay-guided (15.7 months, 95%  CI 0.1-32.7
months) and empirical groups (12.6 months, 95%  CI 9.0-
16.2; p=0.642; Figure 3D; Table II). However, the platinum-
sensitive subgroup by the assay showed a trend toward
favorable OS compared to the empirical group (median, not
reached versus 12.6 months for the platinum-sensitive versus
empirical group; p=0.134; Figure 3B). 
In addition, no differences in PFS or OS between the
assay-guided and empirical groups were observed in the
subgroup analysis according to nonplatinum agents (Table II). 
Prognosticators for PFS and OS. Significant factors by
univariate analysis, matched variables (ECOG PS, stage,
chemotherapeutic agents), and choice of chemotherapy
(assay-guided versus empirical) were put into the multivariate
analysis (Table III). ECOG PS was the only prognosticator for
both PFS (hazard ratio, 3.33) and OS (hazard ratio, 2.74).
Assay-guided versus empirical chemotherapy was not a
prognosticator. 
ANTICANCER RESEARCH 29: 4243-4250 (2009)
4246
Table II. Comparison of treatment outcomes based on regimens between assay-guided versus empirical groups.
Assay group Empirical group P-value
Gemcitabine+platinum (n=9) (n=31)
Sensitive to both/pl/nonpl/neither (% ) 33/0/33/34 - -
Response rate (% ) 55.6 45.2 0.712
PFS (mo), median (95%  CI) 3.8 (0.3-7.3) 5.3 (3.9-6.7) 0.967
OS (mo), median (95%  CI) 9.0 (2.9-15.1) 12.6 (6.5-18.7) 0.860
Paclitaxel+platinum (n=11) (n=39)
Sensitive to both/pl/nonpl/neither (% ) 27/37/9/27 - -
Response rate (% ) 54.5 30.8 0.147
PFS (mo), median (95%  CI) 5.8 (0.1-12.3) 4.2 (2.7-5.7) 0.285
OS (mo), median (95%  CI) 24.1 (7.5-40.7) 11.9 (8.7-15.1) 0.332
Vinorelbine+platinum (n=7) (n=23)
Sensitive to both/pl/nonpl/neither (% ) 29/29/29/13 - -
Response rate (% ) 28.6 40.9 0.677
PFS (mo), median (95%  CI) 3.6 (0.5-6.7) 5.1 (0.1-13.0) 0.367
OS (mo), median (95%  CI) 11.2 (NA) NR 0.892
Total patients (n=27) (n=93)
Response rate (% ) 48.1 38.0 0.347
PFS (mo), median (95%  CI) 4.4 (2.7-6.1) 4.8 (3.5-6.1) 0.918
OS (mo), median (95%  CI) 15.7 (0.1-32.7) 12.6 (9.0-16.2) 0.642
Both/pl/nonpl/neither: Sensitive to both drugs/platinum/nonplatinum/neither; PFS: progression-free survival; mo: month; CI: confidence interval;
OS: overall survival; NA: not available; NR: not reached.
Discussion
Palliative chemotherapy with doublet regimens using
platinum or third-generation agents such as taxanes and
gemcitabine is the standard of care in advanced NSCLC (8-
10). However, recent studies continue to indicate that we
have reached an efficacy plateau with chemotherapy
combination with or without a platinum agent. As one of
various strategies to overcome this problem, chemosensitivity
and resistance assays have been studied in NSCLC (11-14).
Until now, studies of this type have been limited in number
(15). Moreover, no randomized trials comparing assay-
guided chemotherapy to empirical chemotherapy have been
performed on NSCLC. In the current study, based on our
previously reported data on ATP-CRA-guided platinum-
based chemotherapy in unresectable NSCLC, we set a
control arm consisting of individuals with empirical
platinum-based chemotherapy. Patients were not randomly
assigned to either of the groups. However, all patients were
treated at the same institute within the same period using
identical therapeutic standards. Both treatment directives and
follow-up for the controls were identical compared to the
ATP-CRA group. Patients from both groups were well
matched for all criteria known to influence outcome.
Therefore, the two arms in our study are comparable even
though this study was not designed prospectively. 
In our study on platinum-based chemotherapy in
unresectable NSCLC, RRs according to regimens were not
statistically different, which was in accordance with previous
reports (16-18). The platinum-sensitive group by ATP-CRA
showed a higher response rate than the empirical group as in
vitro assay-guided chemotherapy has been reported to show
higher RRs than empirical chemotherapy in various types of
cancer (19, 20). This result encourages the further testing of
ATP-CRA in clinical trials. However, when the platinum-
sensitive and resistant groups were combined in the assay
group, the assay group only had a trend toward a slightly
higher RR than the empirical group. Moreover, in vitro
assay-guided chemotherapy was not more beneficial than
empirical chemotherapy in terms of survival (PFS or OS) in
the current study. 
Theoretically, ATP-CRA-guided chemotherapy should be
superior to empirical chemotherapy. In reality, it is not. There
are several possible explanations for the non-superiority of
assay-guided chemotherapy in our study. Firstly, the
proportion of patients who are going to experience benefits
from platinum-based chemotherapy may be predetermined
from the pool of NSCLC patients. This hypothesis is
supported by the previous reports that in advanced NSCLC,
none of platinum-based doublets as a first-line chemotherapy
was superior to others (16-18). Under this assumption, the
efficacy of platinum-based chemotherapy cannot be
improved, even with assay-guided chemotherapy. 
Secondly, there was not enough variety of
chemotherapeutic regimens in the assay-guided group, in
which nonplatinum doublets were not allowed. In designing
this trial, a chemotherapeutic regimen was set as a matching
variable between the assay-guided and empirical groups to
augment comparability. On the contrary, this point may have
offset potential differences in efficacy between the assay-
guided and empirical chemotherapies. For example, even
patients with platinum resistance received platinum-based
chemotherapy. Alternatively, they could have received
nonplatinum doublets as another option in platinum-resistant
Moon et al: In Vitro Assay-guided versus Empirical Chemotherapy in NSCLC
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Figure 2. Comparison of response rates: platinum-resistant by ATP-CRA
(PR), platinum-sensitive by ATP-CRA (PS) and empirical group (EG).
Figure 3. Progression-free survival (PFS; A, C) and overall survival
(OS; B, D). PS, Platinum-sensitive; PR, platinum-resistant; AG, assay
group; EG, empirical group; NR, not reached.
cases. Third-generation-based nonplatinum combinations
have been reported to be possible alternatives to platinum-
based doublets (8). In addition, Figure 3A and 3B show that
the survival curves of the empirical group are located
between platinum-sensitive and -resistant groups, suggesting
patients receiving drugs to which they were in vitro sensitive
had the best outcomes and those receiving drugs to which
they were in vitro resistant had room for improved survival
with alternative drugs. Our ATP-CRA could predict
chemoresistance rather than chemosensitivity as we
previously reported (3). From the perspective of this
chemoresistance assay, further randomized trials should be
designed. 
Thirdly, biopsied tissue used in ATP-CRA may have not
been representative of individual patients’ whole tumor (21-
23). This has always been a big issue for in vitro
chemosensitivity tests. Although this is not the case in
NSCLC, Cho and colleagues reported that ATP-CRA results
changed according to depth of invasion of the tested tissue
in advanced colorectal cancer (24). Therefore, in further
clinical trials, specimens for chemosensitivity tests should be
taken from various parts of the whole tumor.
When patients are sensitive to both platinum and
nonplatinum agents, drugs selected by in vitro tests are the
most ideal choice. In this study, however, both types of
drugs were administered in only 30%  of patients because
only 30%  of patients had tumors with sensitivity to both
drugs. Moreover, platinum sensitivity was not inferior to
doublet sensitivity in predicting efficacy of platinum-
based doublets in our study (data not shown). Therefore,
we recommend that only platinum be tested with ATP-
CRA and platinum-resistant tumors be treated with
nonplatinum combinations in clinical trial settings. Low
expression of the excision repair cross-complementing 1
(ERCC1)  gene has been reported to predict platinum-
sensitivity in NSCLC (25, 26). Therefore, platinum
sensitivity with ATP-CRA is worth comparing to ERCC1
testing in NSCLC.
In conclusion, although ATP-CRA-guided chemotherapy
did not show superior efficacy compared to empirical
chemotherapy in unresectable NSCLC, ATP-CRA may be
helpful in selecting platinum-responsive patients. We
consider that nonplatinum doublets in platinum-resistant
patients by ATP-CRA may be a more adapted approach than
platinum-based doublets in future clinical trials. 
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